Medtronic said on Friday that the Food and Drug Administration approved its drug-coated stent Endeavor.
The still-ailing market for popular heart devices known as stents is headed for a war over market share, with two new products expected soon.
The U.S. Supreme Court will hear arguments Tuesday in a case that could have major implications for Medtronic Inc. and other makers of medical devices.
Stocks were still poised for a higher open even after the mortgage finance giant Freddie Mac reported a wider loss and a government report showed building permits hit a 14-year low.
Of the 51 cases the U.S. Supreme Court agreed to hear this term, which began in October, eight directly affect small business.
The cause of implantable heart defibrillators took a hit Tuesday when researchers reported the results of two studies that failed to reach their objectives.
U.S. stocks were just slightly higher at the start of trading Monday as investors considered a new plan to help major banks deal with troubled debt.
Stocks advanced in early trading Thursday, moving into record territory, on a narrower-than-expected trade gap and strength in overseas markets.
Medtronic's stock price dipped 2 percent after the FDA released documents Friday that questioned the effectiveness of the company's experimental stent Endeavor.
Five makers of medical device implants have made agreements with the U.S. government to resolve fraud concerns over industry practices, with four companies paying a total of $310 million, federal prosecutors said Thursday.
Medtronic said on Friday that the Food and Drug Administration approved its drug-coated stent Endeavor.
The still-ailing market for popular heart devices known as stents is headed for a war over market share, with two new products expected soon.
The U.S. Supreme Court will hear arguments Tuesday in a case that could have major implications for Medtronic Inc. and other makers of medical devices.
Stocks were still poised for a higher open even after the mortgage finance giant Freddie Mac reported a wider loss and a government report showed building permits hit a 14-year low.
Of the 51 cases the U.S. Supreme Court agreed to hear this term, which began in October, eight directly affect small business.
The cause of implantable heart defibrillators took a hit Tuesday when researchers reported the results of two studies that failed to reach their objectives.
U.S. stocks were just slightly higher at the start of trading Monday as investors considered a new plan to help major banks deal with troubled debt.
Stocks advanced in early trading Thursday, moving into record territory, on a narrower-than-expected trade gap and strength in overseas markets.
Medtronic's stock price dipped 2 percent after the FDA released documents Friday that questioned the effectiveness of the company's experimental stent Endeavor.
Five makers of medical device implants have made agreements with the U.S. government to resolve fraud concerns over industry practices, with four companies paying a total of $310 million, federal prosecutors said Thursday.
Health care executives speaking at the Bear Stearns healthcare conference in New York said the best opportunities for growth are overseas, and Medtronic's new CEO pointed to China as the world's hottest international market.
Stocks opened sharply higher Wednesday as credit markets calmed down a bit and speculation grew on Wall Street that a Fed rate cut was coming, maybe soon.
Medtronic Inc. on Tuesday reported healthy gains in sales and earnings but analysts were disappointed by revenue growth.
Medical technology company Medtronic Inc. said Friday that it would acquire Kyphon Inc. for $3.9 billion to expand its spinal treatment business.
U.S. stocks were mixed at Friday's open, as a better-than-expected economic growth report extinguished only some of the credit and housing fears that led to the year's second biggest Dow drop.
A panel of FDA experts recommended the approval of an artificial spine disc from Medtronic on Tuesday, one day after the agency granted market approval to another one of the company's neck discs.
The first-ever spinal replacement disc for the neck could hit the U.S. market as soon as this month.
1. Cell-Phone Giants Start Courting Coders
U.S. stocks were set for a lower open Wednesday after a key inflation gauge came in above expectations.
The medical device maker Medtronic is planning three major product launches this year including an implanted device meant to be an early warning system for heart disease patients.
As Big Pharma's pipeline for blockbuster drugs slows, med tech giants are helping to fill the gap with devices that treat everything from migraines to severe depression.
The Food and Drug Administration said it completed an investigation of Medtronic over its recently launched Concerto implantable heart devices but hasn't found anything to indicate that the devices are unsafe.
The Food and Drug Administration is investigating the medical device maker Medtronic, reportedly over its recently launched Concerto implantable defibrillators.
Stephen Levy knows how lucky he was to sell when he did. He put his San Diego penthouse on the market in August 2005 for $2.65 million, more than double what he had paid for it in 1998. That October he got an offer for $2.25 million but turned it down. It would be months before he got his next offer. Luckily for him, he was finally able to sell, closing for $2.1 million.
Growth in the relatively new, $5 billion worldwide market for the drug-coated stents might have already peaked.
An FDA advisory committee will be taking a hard look this week at drug-coated stents, which the agency approved back in 2003 to prevent the arteries from re-closing better than non-drug stents.
Medtronic's experimental vertebrae device is pretty much a lock to win FDA approval. It's the approval of Medicare that going to be harder to win - and essential for the device's success.
Healthcare giants like Johnson & Johnson and Medtronic are not the only companies battling to solve the riddle of your aching lower back.
Everyone thinks they know what's involved in creating a new drug: $800 million in R&D, followed by a 10-year machete march through the thickets of FDA regulations. That daunting prospect is hardly the thing to get an entrepreneur's heart pumping.
EVERYONE THINKS THEY KNOW WHAT'S INVOLVED in creating a new drug: $800 million in R&D, followed by a 10-year machete march through the thickets of FDA regulations. That daunting prospect is hardly ...
Medtronic ranks no. 235 on this year's list of the FORTUNE 500, with $10,054.6 million in revenues, up 10.6% from the previous year. The Minneapolis-based company was ranked no. 246 on the 2005 list. Its 2005 profits were $1,803.9 million, down 7.9% from a year earlier.
SECRET NO. 01: Compare everything you do against your rivals. HP
Johnson & Johnson was going to buy Guidant to grow its strongest line of business. But J&J lost. So it needs to buy something else to keep its most promising business rolling.
A revolt of top talent is brewing across corporate America, say dozens of top executives, consultants and researchers, suggesting that it's time to reenergize the stale "work-life" debate -- by starting at the top.
So who's next in line for a Johnson & Johnson buy-out?
Stocks slipped Wednesday as investors ignored falling oil prices and instead focused on long-term interest rates that hit seven-month highs and mixed quarterly earnings.
JoAnn Mason, 71, from Hemet, California experienced episodes of syncope (unexplained fainting) before having an electronic implant surgically inserted under the skin near her collarbone that helped doctors solve the problem.
A published report says the Justice Department and many hospitals are looking into financial arrangements between medical device manufacturers and surgeons who typically decide which device will be given to a patient.
Medtronic stock trading could be volatile Wednesday as the company awaits approval to sell medical devices in Europe, according to a newspaper report.
Corporate directorships are becoming more lucrative -- again, according to a published report.
NEW YORK (CNN/Money) - Any romance needs to start with a spark, some sizzle, if you will. But for true love to blossom, there needs to be more than just sex appeal.
COMPUTER HARDWARE
A slight easing of oil prices could set U.S. stocks higher at the start of trading Monday while investors weigh more quarterly results, including Dow component 3M.
In early April, the powers behind the Dow Jones industrial average booted onetime titans AT&T, Eastman Kodak and International Paper, and added American International Group, Pfizer and Verizon. It ...
Wall Street will try to ignore the on-again off-again oil fever on Tuesday after stocks ended flat in the previous session after caution returned that oil prices could rise further despite Saudi Arabia's attempt to boost production.
A medical trial showing the benefits of implantable defibrillators for patients suffering from heart failure boosted shares of cardiovascular device makers Medtronic and Guidant Monday.
"I Have a Cast-Iron Stomach"
Technology stocks clung to gains Thursday as investors hunted down bargains after the Nasdaq's 2.5 percent sell-off the previous session, but traders became leery that Friday's U.S. employment report could come out weaker than expected.
Cisco Systems' higher-than-expected earnings failed to satisfy investors on Wednesday, but Pixar Animation's quarterly results impressed Wall Street after the closing bell.
Year after year of double-digit insurance-premium hikes have some small businesses fearing for their health. Some have stopped providing health insurance. But an increasing number are offering "con...
Tall and straight-backed as a church pew, Bill George has a way of speaking that conjures up a single word: vicar. His even, Midwestern speech is sprinkled with words like "mission," "calling," an...
R.J. Pittman is a classic business daredevil, a 33-year-old with a new technology and a taste for adventure. Larry Brilliant is a more established quantity, a four-time entrepreneur who co-founded ...
A weird but true fact about modern medical insurance: The healthiest way to deal with a managed-care company is to own stock in it. If you're covered by a medical benefits plan and actually go to t...
Medtronic's new CEO Art Collins has a tough act to follow. His predecessor, William George, transformed Medtronic from a simple pacemaker manufacturer into the world's largest diversified medical d...
We won't know for months whether the recession has officially ended, but it seems that folks all over Wall Street are high-fiving one another over the turnaround. Since September, Standard & Poor's...
How we pick the 100 best
Thanks to the heart troubles of Vice President Dick Cheney, pacemakers and stents have been front-page news. Yet the companies that make such devices are at a crossroads. In the 1990s, industry lea...
The economy is shifting into a lower gear. You know that much. So what does that mean for the 100 Best Companies to Work For, FORTUNE's annual list of employers that know how to treat workers right...
Bill George cruises the long basement hallway between buildings at headquarters, and as he moves smartly from A to B, backs straighten, chins rise, and smiles appear within a 30-foot radius of his ...
The markets have been highly volatile this year, so it's no surprise that the eight stocks we chose as our best investments for 2000 have produced widely varied returns. Our top pick jumped 55%; ou...
STOCKS Analog Devices, Automatic Data Processing, Cintas, Cisco Systems, Coca-Cola, Colgate-Palmolive, Gillette, Medtronic, Merck, Microsoft, Paychex, Staples, State Street, Stryker and Vodafone Ai...
When our writers and editors sat down to discuss the best investments for the year ahead, the historically high price of the stock market was much on our minds. Is the moment near when unloved valu...
Struggling hard to regain rhythm
Way back in 1949, Earl Bakken, the co-founder of Medtronic, outlined his 100-year plan. His company then was nothing more than a hospital-equipment repair shop, and the notion of implanting electri...
STOCKS More than 25 stocks, almost all large-caps. Favorites include Abbott Laboratories, American International Group, Coca-Cola, General Electric, IBM, Intel, Medtronic, Microsoft, Northern Trust...
The way most investors pick stocks today, you'd think that dividends were worthless. The yield on the S&P 500 is currently running a pitiful 1.2%, its lowest level in more than 75 years. Yet recent...
You now know how you can sort through large groups of stocks using screens. But what if you want to check up on one stock? I'll use an example to show you how. Recently, I saw that Medtronic (MDT),...
John Schroer has been on a roll. His home team, the Denver Broncos, won the Super Bowl, and his fund, $1.6 billion Invesco Health Sciences, topped all health-sector funds for 1998, returning 43%.
Saying nice things about cardiac-care companies is easy. Their products keep you alive--can't beat that for a slogan. And they cater to well-off, well-fed, aging markets in North America and Wester...
This past autumn, Tom Curry plunked down in the den of his Sturbridge, Mass., home, fired up the family computer, and started looking for work. Until then the computer had mostly been the domain of...
By now, most of us have been schooled to believe we'll spend the rest of our careers jumping from job to job, working ever harder to prove our mettle to cranky bosses, and getting promoted much les...
Just how rich would you be if you had bought all 43 stocks recommended in this column between January and June? Well, who knows exactly, but you would be smiling like the cat that ate the entire av...
THIS MONTH: --What to do with those Dow dogs now --Three acquisitive insurers offer gains of up to 38%. --A once-dim bulb glows with high-tech potential.
We caught up with Marshall Acuff in the Edinburgh airport, on his way to the Scottish highlands for a little shooting. The Smith Barney equity strategist was eerily on target in our July 8 issue ("...
THIS MONTH:
Sandy Climan, 40 Executive vice president MCA
Three years ago, Steven Schussler was headed for either restaurant heaven or the psychiatric ward. Living in the company of 45 parrots, four toucans, two tortoises, and an iguana--and changing diap...
REMEMBER THOSE OLD NAUTIcal words of wisdom? Red sky at night, sailors' delight. Red sky at morning, sailors take warning. Well, it's nearly morning in 1996, and here's our warning. Forget about sm...
As you patrol the corridors of corporate America, you hear more and more stories like the one about Gary Ellis. Everybody knew he was a fast-tracker headed for the top at Medtronic Inc., the world'...
Stocks of companies based in Cincinnati outperformed those of 23 other metropolitan areas in the third quarter, according to the exclusive MONEY/ Nordby Cities Index. It is composed of a series of ...
How does your company recruit technical workers? Still hanging that tacky job openings sign by the plant gate? Or maybe you're running cryptic classifieds. Are you happy with the results? As techni...
An often overlooked plus from America's huge investment in medical R&D is its salubrious impact on the trade balance. The U.S. exported $11 billion of health care equipment and drugs last year, $3....
ONLY ONE thing will grow faster than the children in this family: the bills. Turn around and the brood will need college tuition. Turn around again, and Mom and Dad will face retirement. To provide...
''The first principle of winning is not to lose.'' That's the motto of Robert Hoerle, 55, whose staff gave him that teddy bear when he was named chairman of the capital management unit at Reich & T...
IT'S BEEN a long time coming, but American manufacturers finally have reasons to be optimistic. Profits are rising, and so are exports. With the engines of many industries revved up to capacity, th...
Before Bing Carlin buys a stock, he tries to get to know the company's top executives. For fund managers whose companies are all over the globe, that would be impossible. But Carlin, the 51-year-ol...
| Most Viewed | Most Emailed | Top Searches |
Video
